Loading company…
Ratio Therapeutics develops radiopharmaceutical treatments and diagnostics for cancer.
Founded in 2021 and based in Massachusetts, Ratio Therapeutics develops radiotherapeutics and diagnostics using its Trillium and Macropa technology platforms. Its programs use radionuclides and compounds including peptides and antibodies for cancer treatment and diagnosis. In July 2026, it raised USD 70 million in Series C funding from Catalio Capital Management, Eli Lilly and Company, Wasatch Group, Duquesne Family Office LLC Profit Sharing Plan and Bristol-Myers Squibb Company.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in